SAN DIEGO, April 16 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel medicines for the treatment of cancer and infectious, respiratory and autoimmune diseases, announced today the appointment of Kent Snyder to its Board of Directors.
